Home

KENNETH B LEE JR

CIK 1208570 · last filed 2023-06-15

KENNETH B LEE JR is a corporate insider who has filed 62 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for BCRX, was dated Jun 15, 2023. Across all open-market trades the lifetime net is +$5.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $559.2K across reported positions. 12 SEC filings were submitted jointly with John Crumpler.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$559.2K

Companies

8

Total Filings

62

Lifetime Open-Market Net

$5.74M

Filer Profile

Reported Address
7100 WEST CREDIT AVENUE, SUITE 101
C/O ARALEZ PHARMACEUTICALS INC.
MISSISSAUGA, A6 L5N 0E4
Related Filers
John Crumpler — 12 joint filings, latest 2018-10-24
ROBERT ALEXANDER INGRAM — 12 joint filings, latest 2018-10-24
Douglas MD Reed — 12 joint filings, latest 2018-10-24
Clay Thorp — 10 joint filings, latest 2018-06-01
Hatteras Venture Advisors IV SBIC, LLC — 7 joint filings, latest 2018-06-01
Hatteras Venture Advisors III, LLC — 5 joint filings, latest 2018-10-24
MAXYGEN INC — 5 joint filings, latest 2012-06-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BCRX Director 68,863 $8.12 $559.2K -$245.6K 16 2023-06-15
HYPERION DEFI, INC. (EYEN) Delisted Director 807 $15.82 $12.8K $54.5K 7 2022-06-21
Aralez Pharmaceuticals Inc. (ARLZ) Delisted Director 102,952 — — $21.1K 7 2017-05-12
Clearside Biomedical, Inc. (CLSD) Delisted 10%+ Owner 111,725 $0.35 $39.3K $6.00M 1 2016-06-07
POZEN INC /NC (POZN) Delisted Director 97,495 — — -$96.5K 12 2015-06-25
INSPIRE PHARMACEUTICALS INC (ISPH) Delisted Director 0 — — $7.8K 7 2011-05-16
OSI PHARMACEUTICALS INC (OSIP) Delisted Director 0 — — $0 4 2010-06-07
CV THERAPEUTICS INC (CVTX) Delisted Director 24,265 — — $0 4 2009-04-16

Recent Filings

62 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-15 BCRX Grant (A) +16,745 $0 EDGAR
2023-02-02 BCRX Exer (M) +15,000 $25.6K EDGAR
2022-06-21 HYPERION DEFI, INC. (EYEN) Delisted Grant (A) +22,222 $0 EDGAR
2022-06-09 BCRX Grant (A) +12,866 $0 EDGAR
2022-05-23 HYPERION DEFI, INC. (EYEN) Delisted Buy (P) +10,000 $22.0K EDGAR
2021-11-22 HYPERION DEFI, INC. (EYEN) Delisted Grant (A) +6,963 $0 EDGAR
2021-09-15 BCRX Mixed +9,000 -$43.8K EDGAR
2021-06-15 HYPERION DEFI, INC. (EYEN) Delisted Buy (P) +6,000 $32.5K EDGAR
2021-05-27 BCRX Grant (A) — $0 EDGAR
2020-09-15 HYPERION DEFI, INC. (EYEN) Delisted Grant (A) +7,288 $0 EDGAR
Showing 1–10 of 62
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.